Scarica l'app Stockscreener
0.2781
13.97%
-0.0452
Dopo l'orario di chiusura:
.28
0.0019
+0.68%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BLRX Giù?
Forum
Previsione
Frazionamento azionario
Bioline Rx Ltd Adr Borsa (BLRX) Ultime notizie
BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - Yahoo Finance
BioLineRx stock hits 52-week low at $0.38 amid market challenges - Investing.com
BiolineRx Ltd. Announces New Direct Offering of Shares - TipRanks
SEC Form 424B5 filed by BioLineRx Ltd. - Quantisnow
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 - Benzinga
BioLineRx Granted Extension to Meet Nasdaq Requirements - TipRanks
BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials - TipRanks
BioLineRx stock hits 52-week low at $0.39 amid market challenges - Investing.com India
BioLineRx Secures Extended U.S. Patent for Motixafortide - TipRanks
BioLineRx secures US patent for cancer drug motixafortide - Investing.com
BioLineRx secures US patent for cancer drug motixafortide By Investing.com - Investing.com UK
BioLineRx stock hits 52-week low at $0.43 amid market challenges - Investing.com
Riding the Waves: A Guide to Investing in BLRX Stock - The InvestChronicle
Market Insight: Bioline Rx Ltd ADR (BLRX)’s Notable Drop, Closing at 0.46 - The Dwinnex
BioLineRx stock hits 52-week low at $0.5 amid market challenges - Investing.com
BioLineRx Ltd. Shareholders Approve Key Resolutions - TipRanks
Bioline Rx Ltd ADR (BLRX) Stock: A Year of Market Fluctuations - The InvestChronicle
Stock Market Recap: Bioline Rx Ltd ADR (BLRX) Concludes at 0.54, a -13.53 Surge/Decline - The Dwinnex
A new trading data show Bioline Rx Ltd ADR (BLRX) is showing positive returns. - SETE News
Metric Analysis: Bioline Rx Ltd ADR (BLRX)’s Key Ratios in the Limelight - The Dwinnex
BLRX overperforms with a 0.95 increase in share price - US Post News
Australia Single Molecule, Real-Time (SMRT) Sequencing Market Size & Outlook, 2030 - Grand View Research
BioLineRx Schedules Annual Shareholders Meeting - TipRanks
Financial Analysis: Bioline Rx Ltd ADR (BLRX)’s Ratios Unveil Key Insights - The Dwinnex
BLRX Stock: Exploring Bioline Rx Ltd ADR’s Growth - The InvestChronicle
Earnings call: BioLineRx beats Q2 goals with strong APHEXDA demand - Investing.com
BioLineRx’s Strong Quarter with APHEXDA Growth - TipRanks
Options Volatility and Implied Earnings Moves Today, August 15, 2024 - TipRanks
Bioline Rx Ltd ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Ratio Revelations: Bioline Rx Ltd ADR (BLRX)’s Financial Metrics in the Spotlight - The Dwinnex
There is no doubt that Bioline Rx Ltd ADR (BLRX) ticks all the boxes. - SETE News
Bioline Rx Ltd ADR (BLRX) stock analysis: A simple moving average approach - US Post News
BLRX’s Stock Journey: What Investors Need to Know About Bioline Rx Ltd ADR’s Performance - The InvestChronicle
Financial Analysis: Bioline Rx Ltd ADR (BLRX)'s Ratios Unveil Key Insights – DWinneX - The Dwinnex
Bioline Rx Ltd ADR Inc. (BLRX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
BLRXBioLineRx Reports Second Quarter 2011 Financial Results - br.ADVFN.com
What Can Bioline Rx Ltd ADR (NASDAQ: BLRX) Expect In 2024? – Stocks Register - Stocks Register
Bioline Rx Ltd ADR (BLRX) stock: A year of ups and downs – US Post News - US Post News
Bioline Rx Ltd ADR (BLRX)'s Market Momentum: Closing Strong at 0.69, Down -4.03 – DWinneX - The Dwinnex
BioLineRx Trials New Sickle Cell Gene Therapy - TipRanks
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applicatio - Investing.com India
Understanding the Risks of Investing in Bioline Rx Ltd ADR (BLRX) – Knox Daily - Knox Daily
Earnings call: BioLineRx Q1 2024 results show steady progress - Investing.com India
Earnings call: BioLineRx Q1 2024 results show steady progress By Investing.com - Investing.com
BioLineRx Q1 Success with APHEXDA® Growth - TipRanks
Bioline Rx Ltd ADR (BLRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Are Smart Investors Making the Right Decision? Bioline Rx Ltd ADR (BLRX) – Sete News - SETE News
BioLineRx to present new data from CheMo4METPANC Phase 2 at ASCOTipRanks.com - TipRanks
BioLineRx reports positive pancreatic cancer trial results By Investing.com - Investing.com
Examining Bioline Rx Ltd ADR (BLRX) more closely is necessary – US Post News - US Post News
BioLineRx Showcases Promising Cancer Drug Trial Results - TipRanks
BioLineRx Faces Nasdaq Compliance ChallengeTipRanks.com - TipRanks
BioLineRx faces Nasdaq minimum bid price noncompliance By Investing.com - Investing.com
BioLineRx Reveals Cost-Saving Stem Cell Mobilization DataTipRanks.com - TipRanks
BioLineRx Enhances Multiple Myeloma TreatmentTipRanks.com - TipRanks
BioLineRx secures $20 million in BlackRock financing By Investing.com - Investing.com
1.89%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):